According to the 3rd International Consensus Conference for Breast Cancer in Young Women (BCY3), a greater proportion of TNBC and HER-2 positive disease and more advanced stages, with higher recurrence rate, and worse prognosis is observed in young breast cancer patients (≤40 years) than older patients (18). Here, ERBB2 is linked to breast carcinoma.